LLY

Eli Lilly and Company (LLY) is the lead sponsor of 200 active clinical trials listed on ClinicalTrials.gov^[5], including 89 Phase 3^[1], 42 Phase 2^[2], 65 Phase 1^[3], 7 Phase 4^[4].

Trial NCT05723198^[6] evaluates Baricitinib in Areata Alopecia with a target enrollment of 595 participants. Trial NCT06649045^[7] evaluates Orforglipron in OSA with a target enrollment of 600 participants. Trial NCT07218380^[8] evaluates Vepugratinib in Carcinoma, Transitional Cell with a target enrollment of 450 participants.

LLY has 4 Form 4 insider filings recorded at the SEC in the past 30 days^[9].